Engraftment Syndrome
The most likely diagnosis in a patient after autologous stem cell transplantation presenting with diffuse erythematous rash and bilateral pulmonary infiltrates is engraftment syndrome (ES).
Clinical Reasoning
This presentation is classic for engraftment syndrome, which occurs around the time of neutrophil recovery following autologous HSCT. The combination of diffuse rash and pulmonary infiltrates in this specific post-transplant context strongly points to ES rather than infection or other complications 1.
Diagnostic Criteria
Based on the Maiolino criteria, ES is diagnosed when a patient has non-infectious fever PLUS any of the following 1:
- Skin rash
- Pulmonary infiltrates
- Diarrhea
Your patient already meets two of these criteria (rash and pulmonary infiltrates), making ES the primary diagnosis to consider.
Timing and Context
ES typically occurs at a median of 14 days post-transplant (range 8-27 days), coinciding with or immediately preceding neutrophil engraftment 2. The syndrome affects approximately 20-26% of autologous HSCT recipients 1, 3. After autologous transplantation specifically, patients are primarily at risk for complications during Phase I (the first 30 days), when neutropenia and mucosal barrier breakdown dominate the clinical picture 4.
Key Distinguishing Features
Why this is likely ES and not infection:
- The bilateral pulmonary infiltrates in ES are characteristically non-infectious and atypical in appearance
- Fever in ES does not respond to standard antibiotic regimens 5
- The constellation of symptoms (fever + rash + pulmonary findings) occurring around engraftment is pathognomonic
Why this is likely ES and not acute GVHD:
- Acute GVHD is exceedingly rare after autologous transplantation 4
- When it does occur in autologous recipients, it presents as a "mild, self-limited illness" 4
- True GVHD "occurs primarily among allogeneic recipients, particularly those receiving matched, unrelated donor transplants" 4
Additional Clinical Features to Assess
Look for these supporting findings that commonly accompany ES 2, 1, 3:
- Weight gain (85% of cases) - often significant fluid retention
- Eosinophilia
- Pruritus
- Hypoalbuminemia
- Fatigue or lassitude
Management Approach
Immediate treatment with systemic corticosteroids is the standard of care 5, 1, 3, 6:
Initiate corticosteroids promptly - Most patients show dramatic improvement within 24-48 hours of starting treatment 5, 6
Typical regimen: Methylprednisolone 1-2 mg/kg/day (or prednisone equivalent) for approximately one week, then taper based on clinical response
Discontinue unnecessary antimicrobials - One major benefit of recognizing ES is avoiding prolonged, unnecessary antibiotic and antifungal therapy 1
Clinical Pitfalls
Common diagnostic errors:
- Misdiagnosing ES as infectious pneumonia, leading to escalating antimicrobial therapy without benefit 5
- Confusing ES with acute GVHD in autologous recipients (extremely unlikely) 7
- Failing to recognize periengraftment respiratory distress syndrome (PERDS), the severe form of ES with up to 21% mortality 5
Red flags requiring intensive monitoring:
- Severe respiratory distress or hypoxemia - may require ICU-level care 6
- Altered mental status
- Rapid clinical deterioration despite antibiotics
Prognosis
With appropriate corticosteroid treatment, ES is generally self-limited with excellent outcomes 3. However, delayed recognition can lead to:
- Prolonged hospitalization (significantly longer than patients without ES) 1
- Unnecessary exposure to antimicrobial agents 1
- Potential progression to severe PERDS in untreated cases 5
The key is recognizing this syndrome early and initiating corticosteroids rather than continuing to escalate antimicrobial coverage for presumed refractory infection.